Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Nicolás Jose Rodriguez

Is MariMed A Safe Haven In The Wake Of Florida's Cannabis Legalization Defeat?

Cannabis company MariMed Inc. (NASDAQ:MRMD) released its Q3 2024 results on November 6, announcing revised guidance for the fiscal year. While the company expects an 18–20% decline in EBITDA – down from its prior projection of flat to 2% growth – it raised its sales guidance to a 6–8% increase, up from 5–7%. These adjustments align closely with earlier projections from Zuanic & Associates, a cannabis industry research firm.

  • Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. You can’t afford to miss out if you're serious about the business.
Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.